RXRX insider transaction filings
RECURSION PHARMACEUTICALS, INC. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-16. Screen RXRX transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 10 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 4 legs across 4 filings by 2 insiders — 122,408 shares, $435,022 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 6.
- Largest priced transaction: sale of 40,000 shares @ $3.96 ($158,500) by Borgeson Blake, filed 2026-07-09.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Borgeson Blake — Director | 3 | — | 3 legs · 100,000 sh · $356,200 | — |
| Khan Najat — CEO and President, Director | 2 | — | 1 leg · 22,408 sh · $78,822 | 1 |
| Taylor Ben R — Chief Financial Officer | 2 | — | — | 2 |
| Dar Zavain — Director | 1 | — | — | 1 |
| Hallett David — Chief Scientific Officer | 1 | — | — | 1 |
| Li Dean Y — Director | 1 | — | — | 1 |
Recent Form 4 filings — RECURSION PHARMACEUTICALS, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-16 | 4 | Taylor Ben R — Chief Financial Officer | Tax withholding (F): 5,396 @ $3.41 | EDGAR |
| 2026-09-10 | 4 | Khan Najat — CEO and President, Director | Sale (S): 22,408 @ $3.52 | EDGAR |
| 2026-09-02 | 4 | Borgeson Blake — Director | Sale (S): 30,000 @ $3.34 | EDGAR |
| 2026-08-18 | 4 | Taylor Ben R — Chief Financial Officer | Tax withholding (F): 25,018 @ $3.16 | EDGAR |
| 2026-08-18 | 4 | Hallett David — Chief Scientific Officer | Tax withholding (F): 26,657 @ $3.16 | EDGAR |
| 2026-08-18 | 4 | Khan Najat — CEO and President, Director | Tax withholding (F): 80,498 @ $3.16 | EDGAR |
| 2026-08-06 | 4 | Borgeson Blake — Director | Sale (S): 30,000 @ $3.25 | EDGAR |
| 2026-07-09 | 4 | Borgeson Blake — Director | Sale (S): 40,000 @ $3.96 | EDGAR |
| 2026-07-02 | 4 | Dar Zavain — Director | Grant/award (A): 5,109 @ $0 | EDGAR |
| 2026-07-02 | 4 | Li Dean Y — Director | Grant/award (A): 3,747 @ $0 | EDGAR |
| 2026-06-22 | 4 | Borgeson Blake — Director | Grant/award (A): 88,424 @ $0 | EDGAR |
| 2026-06-22 | 4 | Michor Franziska — Director | Grant/award (A): 88,424 @ $0 | EDGAR |
| 2026-06-22 | 4 | Sun Elaine D — Director | Grant/award (A): 88,424 @ $0 | EDGAR |
| 2026-06-22 | 4 | Dar Zavain — Director | Grant/award (A): 88,424 @ $0 | EDGAR |
| 2026-06-22 | 4 | Li Dean Y — Director | Grant/award (A): 88,424 @ $0 | EDGAR |
| 2026-06-22 | 4 | Bumpus Namandje — Director | Grant/award (A): 88,424 @ $0 · Sale (S): 3,963 @ $3.18 | EDGAR |
| 2026-06-22 | 4 | HERSHBERG ROBERT — Director | Grant/award (A): 88,424 @ $0 | EDGAR |
| 2026-06-17 | 4 | Taylor Ben R — Chief Financial Officer | Tax withholding (F): 5,396 @ $3.15 | EDGAR |
| 2026-06-05 | 4 | Khan Najat — CEO and President, Director | Sale (S): 23,588 @ $3.58 | EDGAR |
| 2026-06-05 | 4 | Gibson Christopher — Director | Conversion (C): 40,000 @ $0 · Sale (S): 40,000 @ $3.62 · Conversion (C): 40,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Bumpus Namandje — Director | Sale (S): 4,386 @ $3.54 | EDGAR |
| 2026-06-04 | 4 | Borgeson Blake — Director | Sale (S): 30,000 @ $3.68 | EDGAR |
| 2026-05-27 | 4 | Gibson Christopher — Director | Conversion (C): 40,000 @ $0 · Sale (S): 40,000 @ $3.08 · Conversion (C): 40,000 (derivative) @ $0 | EDGAR |
| 2026-05-19 | 4 | Khan Najat — CEO and President, Director | Tax withholding (F): 62,701 @ $3.04 | EDGAR |
| 2026-05-19 | 4 | Hallett David — Chief Scientific Officer | Tax withholding (F): 26,657 @ $3.04 | EDGAR |
| 2026-05-19 | 4 | Gibson Christopher — Director | Tax withholding (F): 22,821 @ $3.04 | EDGAR |
| 2026-05-19 | 4 | Taylor Ben R — Chief Financial Officer | Tax withholding (F): 25,018 @ $3.04 | EDGAR |
| 2026-05-08 | 4 | Gibson Christopher — Director | Conversion (C): 60,000 @ $0 · Sale (S): 40,000 @ $3.37 · Gift (G): 20,000 @ $0 · Conversion (C): 60,000 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | Borgeson Blake — Director | Sale (S): 30,000 @ $3.52 | EDGAR |
| 2026-04-24 | 4 | Gibson Christopher — Director | Conversion (C): 40,000 @ $0 · Sale (S): 40,000 @ $3.61 · Conversion (C): 40,000 (derivative) @ $0 | EDGAR |
| 2026-04-08 | 4 | Gibson Christopher — Director | Conversion (C): 40,000 @ $0 · Sale (S): 40,000 @ $3.10 · Conversion (C): 40,000 (derivative) @ $0 | EDGAR |
| 2026-04-08 | 4 | Borgeson Blake — Director | Sale (S): 30,000 @ $3.10 | EDGAR |
| 2026-04-08 | 4 | Taylor Ben R — Chief Financial Officer | Tax withholding (F): 48,028 @ $3.11 | EDGAR |
| 2026-04-02 | 4 | Dar Zavain — Director | Grant/award (A): 4,902 @ $0 | EDGAR |
| 2026-04-02 | 4 | Li Dean Y — Director | Grant/award (A): 3,268 @ $0 | EDGAR |
| 2026-03-25 | 4 | Gibson Christopher — Director | Conversion (C): 40,000 @ $0 · Sale (S): 40,000 @ $3.25 · Conversion (C): 40,000 (derivative) @ $0 | EDGAR |
| 2026-03-18 | 4 | Taylor Ben R — Chief Financial Officer | Tax withholding (F): 7,075 @ $3.42 · Sale (S): 7,956 @ $3.39 | EDGAR |
| 2026-03-11 | 4 | Gibson Christopher — Director | Conversion (C): 20,000 @ $0 · Gift (G): 20,000 @ $0 · Conversion (C): 20,000 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | Khan Najat — CEO and President, Director | Sale (S): 28,298 @ $3.35 | EDGAR |
| 2026-03-04 | 4 | Borgeson Blake — Director | Sale (S): 170,000 @ $3.46 | EDGAR |
| 2026-02-19 | 4 | Hallett David — Chief Scientific Officer | Tax withholding (F): 11,908 @ $3.49 | EDGAR |
| 2026-02-19 | 4 | Gibson Christopher — Director | Tax withholding (F): 27,265 @ $3.49 · Conversion (C): 40,000 @ $0 · Sale (S): 40,000 @ $3.46 · Conversion (C): 40,000 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | Taylor Ben R — Chief Financial Officer | Tax withholding (F): 11,908 @ $3.49 · Sale (S): 13,426 @ $3.08 | EDGAR |
| 2026-02-19 | 4 | Khan Najat — CEO and President, Director | Tax withholding (F): 14,280 @ $3.49 | EDGAR |
| 2026-02-10 | 4 | Khan Najat — CEO and President, Director | Grant/award (A): 1,673,546 @ $0 · Grant/award (A): 30,346 @ $0 · Tax withholding (F): 10,364 @ $3.98 | EDGAR |
| 2026-02-10 | 4 | Taylor Ben R — Chief Financial Officer | Grant/award (A): 446,279 @ $0 · Grant/award (A): 24,254 @ $0 · Tax withholding (F): 11,400 @ $3.98 | EDGAR |
| 2026-02-10 | 4 | Hallett David — Chief Scientific Officer | Grant/award (A): 502,064 @ $0 · Grant/award (A): 24,254 @ $0 · Tax withholding (F): 11,400 @ $3.98 | EDGAR |
| 2026-02-06 | 4 | Gibson Christopher — Director | Conversion (C): 40,000 @ $0 · Sale (S): 40,000 @ $4.12 · Grant/award (A): 30,346 @ $0 · Tax withholding (F): 10,364 @ $3.56 · Conversion (C): 40,000 (derivative) @ $0 | EDGAR |
| 2026-02-06 | 4 | Borgeson Blake — Director | Sale (S): 220,000 @ $4.20 | EDGAR |
| 2026-01-22 | 4 | Gibson Christopher — Director | Conversion (C): 40,000 @ $0 · Sale (S): 40,000 @ $4.47 · Conversion (C): 40,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — RECURSION PHARMACEUTICALS, INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-21 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
| 2026-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-18 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-06 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-30 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-25 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-25 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-08 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-26 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=RXRX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →